Xiao-Yao Powder (XYP) has been used for the treatment of liver function disorder, depression and comprehensive syndromes of perimenopausal women for over 2000 years. The present work aims to reveal the tissue distribution characteristics of XYP in young and old female rats contrastively to evaluate rationality and compatibility of herbal medicine, in terms of efficacy and toxicity. An ultra-performance liquid chromatography–tandem mass spectrometry method was used to detect the 14 representative components (albiflorin, paeoniflorin, ferulic acid, senkyunolide I, quercetin, isoliquiritigenin, atractylenolide III, ligustilide, atractylenolide II, liquiritin, liquiritigenin, saikosaponin c, glycyrrhizic acid, and saikosaponin a) in both 2-month-old and 18-month-old female rats. After oral administration of XYP extract (4 g/kg), rats’ tissues (heart, liver, spleen, lung, kidney, brain, stomach, uterus, ovary and small intestine) were taken at time points immediately. The detection was performed on a triple-quadrupole tandem mass spectrometer equipped in positive and negative ionization modes by multiple reaction monitoring (MRM) and an electrospray ionization source. All validation parameters met the acceptance criteria according to regulatory guidelines. The tissue distribution study of XYP confirmed that 14 analytes from the two age groups were mainly distributed in ovary, uterus and liver, which is consistent with the characteristics of XYP in treating liver depression and perimenopausal syndrome. Compared with the young rats, the tissue concentrations of most analytes in old rats group decreased, with the exception of senkyunolide I and Atractylenolide III showing higher levels in brain. The identified target tissues of XYP may help in understanding its pharmacological action in vivo.
| Published in | Science Journal of Analytical Chemistry (Volume 10, Issue 3) |
| DOI | 10.11648/j.sjac.20221003.13 |
| Page(s) | 49-67 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Xiao-Yao Powder (XYP), UPLC-MS/MS, Tissue Distribution
| [1] | Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China, Part 1. The Medicine Science and Technology Press of China, Beijing; 2020. 1464-1462. |
| [2] | Geng, F., Zhang, N., Fang, H., Li, J. M., & Liu, H. Y. (2014). Metabonomic study on protective effect of xiaoyao powder for acute hepatic injury in rats. Zhong Yao Cai, 37, 275–279. |
| [3] | Li, X. J., Ma, Q. Y., Jiang, Y. M., Bai, X. H., Yan, Z. Y., & Liu, Q. et al. (2017). Xiaoyaosan exerts anxiolytic-like effects by down-regulating the TNF-α/JAK2-STAT3 pathway in the rat hippocampus. Scientific Reports, 7 (1), 1-13. doi: 10.1038/s41598-017-00496-y. |
| [4] | Man, C., Li, C., Gong, D., Xu, J., & Fan, Y. (2014). Meta-analysis of Chinese herbal Xiaoyao formula as an adjuvant treatment in relieving depression in Chinese patients. Complementary Therapies in Medicine, 22 (2), 362-370. doi: 10.1016/j.ctim.2014.02.001. |
| [5] | Wang, J. J., Li, X. F., He, S. G., Hu, L. J., & Guo, J. W. (2018). Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat. Journal of Ethnopharmacology, 214, 13-21. doi: 10.1016/j.jep.2017.11.037. |
| [6] | Shi, Y. P. (2004). The application of modified xiao yao san in the treatment of gynaecological diseases. The Journal of Chinese Medicine, 74, 25-30. |
| [7] | Liu, H., Zeng, L., Yang, K., & Zhang, G. (2016). A network pharmacology approach to explore the pharmacological mechanism of xiaoyao powder on anovulatory infertility. Evidence-Based Complementary and Alternative Medicine, 2016, 1-13. doi: 10.1155/2016/2960372. |
| [8] | Kimata, H., Sumida, N., Matsufuji, N., Morita, T., Ito, K., & Yata, N., et al. (1985). Interaction of Saponin of Bupleuri Radix with Ginseng Saponin: Solubilization of Saikosaponin-a with Chikusetsusaponin V. Chemical & Pharmaceutical Bulletin, 33, 2849-2853. doi: 10.1248/cpb.33.2849. |
| [9] | Du, Z. A., Sun, M. N., & Hu, Z. S. (2018). Saikosaponin a ameliorates LPS-induced acute lung injury in mice. Inflammation, 41 (1), 193-198. doi: 10.1007/s10753-017-0677-3. |
| [10] | Lee T. Ho., Park S., You M. H., Lim J. H., Min S. H., & Kim B. Mo. (2016). A potential therapeutic effect of saikosaponin C as a novel dual-target anti-Alzheimer agent. Journal of Neurochemistry, 136 (6), 1232-1245. doi: 10.1111/jnc.13515. |
| [11] | Feng Z. B., Lu Y. P., Wu X. M., Zhao P., Li J. J., & Peng B. et al. (2012). Ligustilide alleviates brain damage and improves cognitive function in rats of chronic cerebral hypoperfusion. Journal of Ethnopharmacology, 144 (2), 313-321. doi: 10.1016/j.jep.2012.09.014. |
| [12] | Kim H. Y., Park J., Lee K. H., Lee D. U., Kwak J. H., & Kim Y. S. et al. (2012). Ferulic acid protects against carbon tetrachloride-induced liver injury in mice. Toxicology, 282 (3), 104-111. doi: 10.1016/j.tox.2011.01.017. |
| [13] | Hu Y., Duan M., Liang S., Wang Y., & Feng Y. (2015). Senkyunolide I protects rat brain against focal cerebral ischemia–reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3. Brain Research, 1605, 39-48. doi: 10.1016/j.brainres.2015.02.015. |
| [14] | Sagara K., Ito Y., Oshima T., Kawaura M., & Misaki T. (2008). Application of Ion-Pair High-Performance Liquid Chromatography to the Analysis of Glycyrrhizin in Glycyrrhizae Radix. Chemical & Pharmaceutical Bulletin, 33, 5364-5368. doi: 10.1248/cpb.33.5364. |
| [15] | Zhao Z. L., Park S. M., Guan L. X., Wu Y. Y,. Lee J. R,. & Kim S. C. et al. (2015). Isoliquiritigenin attenuates oxidative hepatic damage induced by carbon tetrachloride with or without buthionine sulfoximine. Chemico-Biological Interactions, 225, 13-20. doi: 10.1016/j.cbi.2014.10.030. |
| [16] | Zhao Z. Y., Wang W. X., Guo H. Z., & Zhou D. F. (2008). Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behavioural Brain Research, 194 (1), 108-113. doi: 10.1016/j.bbr.2008.06.030. |
| [17] | Xue S., Duan X., Wang C., Liu Z., & Qiang M. (2017). Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. European Journal of Pharmacology, 806, 75-82. doi: 10.1016/j.ejphar.2017.04.021. |
| [18] | Qiu F. M., Zhong X. M., Mao Q. Q., & Huang Z. (2013). Antidepressant-like effects of paeoniflorin on the behavioural, biochemical, and neurochemical patterns of rats exposed to chronic unpredictable stress. Neuroscience Letters, 5, 1113-1116. doi: 10.1016/j.neulet.2013.02.029. |
| [19] | Qiu Z. K., He J. L., Liu X., Zeng J., & Nie H. (2016). Antidepressant-like effects of albiflorin extracted from Radix paeoniae Alba. Journal of Ethnopharmacology, 179, 9-15. doi: 10.1016/j.jep.2015.12.029. |
| [20] | Fu X. Q., Chou G. X., Hiu Y. K., Anfernee K. W. T., Zhao L. H., & Yuen T. K., et al. (2014). Inhibition of STAT 3 signalling contributes to the antimelanoma action of atractylenolide II. Experimental Dermatology, 23 (11), 855-857. doi: 10.1111/exd.12527. |
| [21] | Liu C., Zhao H., Ji Z. H., & Yu X. Y. (2014). Neuroprotection of atractylenolide III from Atractylodis macrocephalae against glutamate-induced neuronal apoptosis via inhibiting caspase signaling pathway. Neurochemical Research, 39, 1753-1758. doi: 10.1007/s11064-014-1370-7. |
| [22] | Gao X. X., Wang P.. Wu L., Liu J. L., & Qin X. M. (2019). Pharmacokinetics-pharmacodynamics and tissue distribution analysis of Low Polar extract of Xiaoyao Powder combined with rat model of chronic unpredictable mild stress. Journal of Liquid Chromatography & Related Technologies, 42 (7-8), 173-183. doi: 10.1080/10826076.2018.1544146. |
| [23] | Abdur R. R., Sultan Z., Mohammad I., Faisal H., Rabea P., & Washim K. et al. (2020). Sayeed A.HPTLC and UPLC-MS/MS Methods for Quality Control Analysis of Itrifal Formulations of Unani System of Medicine. Journal of AOAC International, 103 (3), 649-658. doi: 10.5740/jaoacint.19-0231. |
| [24] | Liu P. P., Zhou H. N., Zheng Q. X., Lu P., & Chen Q. S. (2019). An automatic UPLC-HRMS data analysis platform for plant metabolomics. Plant Biotechnology Journal, 17 (11), 2038. doi: 10.1111/pbi.13180. |
| [25] | Xu M. Y., Xu Z., Xu Q., Zhang H., Liu M. Y., & Geng F. et al. (2018). UPLC-MS/MS method for the determination of 14 compounds in rat plasma and its application in a pharmacokinetic study of orally administered xiaoyao powder. Molecules, 23 (10), 2514. doi: 10.3390/molecules23102514. |
| [26] | Wu L., Zhang Q., Mo W., Feng J., Li S., & Li J. et al. (2017). Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways. Scientific Reports, 7 (1), 1-13. doi: 10.1038/s41598-017-09673-5. |
| [27] | Tang Y. H., Li Y. Y., Yu H. Y., Gao C., Liu L., & Xing M. Y. et al. (2014). Quercetin attenuates chronic ethanol hepatotoxicity: implication of “free” iron uptake and release. Food and Chemical Toxicology, 67, 131-138. doi: 10.1016/j.fct.2014.02.022. |
| [28] | Chekalina N. I., Shut S. V., Trybrat T. A., Burmak Y. H., & Kazakov Y. M. (2017). Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease. Wiadomosci Lekarskie, 70 (4), 707. |
| [29] | Veith C., Drent M., Bast A., Schooten F. J. V., & Boots A. W. (2017). The disturbed redox-balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin. Toxicology and Applied Pharmacology, 336, 40-48. doi: 10.1016/j.taap.2017.10.001. |
APA Style
Jinlian Gu, Mingyue Xu, Fan Zeng, Yue Na, Xinyu Zhong, et al. (2022). Comparative Tissue Distribution Study of Multiple Bioactive Components of Xiao-Yao Powder in Young and Old Rats. Science Journal of Analytical Chemistry, 10(3), 49-67. https://doi.org/10.11648/j.sjac.20221003.13
ACS Style
Jinlian Gu; Mingyue Xu; Fan Zeng; Yue Na; Xinyu Zhong, et al. Comparative Tissue Distribution Study of Multiple Bioactive Components of Xiao-Yao Powder in Young and Old Rats. Sci. J. Anal. Chem. 2022, 10(3), 49-67. doi: 10.11648/j.sjac.20221003.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjac.20221003.13,
author = {Jinlian Gu and Mingyue Xu and Fan Zeng and Yue Na and Xinyu Zhong and Lu Zhang and Fang Geng and Ning Zhang},
title = {Comparative Tissue Distribution Study of Multiple Bioactive Components of Xiao-Yao Powder in Young and Old Rats},
journal = {Science Journal of Analytical Chemistry},
volume = {10},
number = {3},
pages = {49-67},
doi = {10.11648/j.sjac.20221003.13},
url = {https://doi.org/10.11648/j.sjac.20221003.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjac.20221003.13},
abstract = {Xiao-Yao Powder (XYP) has been used for the treatment of liver function disorder, depression and comprehensive syndromes of perimenopausal women for over 2000 years. The present work aims to reveal the tissue distribution characteristics of XYP in young and old female rats contrastively to evaluate rationality and compatibility of herbal medicine, in terms of efficacy and toxicity. An ultra-performance liquid chromatography–tandem mass spectrometry method was used to detect the 14 representative components (albiflorin, paeoniflorin, ferulic acid, senkyunolide I, quercetin, isoliquiritigenin, atractylenolide III, ligustilide, atractylenolide II, liquiritin, liquiritigenin, saikosaponin c, glycyrrhizic acid, and saikosaponin a) in both 2-month-old and 18-month-old female rats. After oral administration of XYP extract (4 g/kg), rats’ tissues (heart, liver, spleen, lung, kidney, brain, stomach, uterus, ovary and small intestine) were taken at time points immediately. The detection was performed on a triple-quadrupole tandem mass spectrometer equipped in positive and negative ionization modes by multiple reaction monitoring (MRM) and an electrospray ionization source. All validation parameters met the acceptance criteria according to regulatory guidelines. The tissue distribution study of XYP confirmed that 14 analytes from the two age groups were mainly distributed in ovary, uterus and liver, which is consistent with the characteristics of XYP in treating liver depression and perimenopausal syndrome. Compared with the young rats, the tissue concentrations of most analytes in old rats group decreased, with the exception of senkyunolide I and Atractylenolide III showing higher levels in brain. The identified target tissues of XYP may help in understanding its pharmacological action in vivo.},
year = {2022}
}
TY - JOUR T1 - Comparative Tissue Distribution Study of Multiple Bioactive Components of Xiao-Yao Powder in Young and Old Rats AU - Jinlian Gu AU - Mingyue Xu AU - Fan Zeng AU - Yue Na AU - Xinyu Zhong AU - Lu Zhang AU - Fang Geng AU - Ning Zhang Y1 - 2022/09/19 PY - 2022 N1 - https://doi.org/10.11648/j.sjac.20221003.13 DO - 10.11648/j.sjac.20221003.13 T2 - Science Journal of Analytical Chemistry JF - Science Journal of Analytical Chemistry JO - Science Journal of Analytical Chemistry SP - 49 EP - 67 PB - Science Publishing Group SN - 2376-8053 UR - https://doi.org/10.11648/j.sjac.20221003.13 AB - Xiao-Yao Powder (XYP) has been used for the treatment of liver function disorder, depression and comprehensive syndromes of perimenopausal women for over 2000 years. The present work aims to reveal the tissue distribution characteristics of XYP in young and old female rats contrastively to evaluate rationality and compatibility of herbal medicine, in terms of efficacy and toxicity. An ultra-performance liquid chromatography–tandem mass spectrometry method was used to detect the 14 representative components (albiflorin, paeoniflorin, ferulic acid, senkyunolide I, quercetin, isoliquiritigenin, atractylenolide III, ligustilide, atractylenolide II, liquiritin, liquiritigenin, saikosaponin c, glycyrrhizic acid, and saikosaponin a) in both 2-month-old and 18-month-old female rats. After oral administration of XYP extract (4 g/kg), rats’ tissues (heart, liver, spleen, lung, kidney, brain, stomach, uterus, ovary and small intestine) were taken at time points immediately. The detection was performed on a triple-quadrupole tandem mass spectrometer equipped in positive and negative ionization modes by multiple reaction monitoring (MRM) and an electrospray ionization source. All validation parameters met the acceptance criteria according to regulatory guidelines. The tissue distribution study of XYP confirmed that 14 analytes from the two age groups were mainly distributed in ovary, uterus and liver, which is consistent with the characteristics of XYP in treating liver depression and perimenopausal syndrome. Compared with the young rats, the tissue concentrations of most analytes in old rats group decreased, with the exception of senkyunolide I and Atractylenolide III showing higher levels in brain. The identified target tissues of XYP may help in understanding its pharmacological action in vivo. VL - 10 IS - 3 ER -
Information
Email: